Ads
related to: docetaxel and carboplatin breast cancer survival rate 20 years later- Clinical Trial Results
Learn About Clinical Trial Results
In Patients Like Yours.
- Nurses Station
Explore Resources Made For Nurses
To Learn About A mTNBC Treatment.
- Prescription Info
Find Dosing Guides & Safety
Information Here.
- Ordering Information
Find Out More About Ordering
A Treatment For Your Patients.
- Oncology Co-Pay Program
Downloadable Resources Available
For Your Patients And Practice
- Resources
Access Tools & Resources Available
To Help You Learn About A Treatment
- Clinical Trial Results
Search results
Results From The WOW.Com Content Network
TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References
Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]
breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor TCHP
In the United States there has been an increase in the 5-year relative survival rate between people diagnosed with cancer in 1975-1977 (48.9%) and people diagnosed with cancer in 2007-2013 (69.2%); these figures coincide with a 20% decrease in cancer mortality from 1950 to 2014. [8]
During the 20-year study period, 8.5 percent of women who had lumpectomies died from breast cancer, nine percent of women who had mastectomies died from the disease, and 8.5 percent of women who ...
By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines.
Ads
related to: docetaxel and carboplatin breast cancer survival rate 20 years later